Emergent BioSolutions Inc. Common Stock (EBS)
Stock · NYSE · Health Care
$6.38as of 10/16/2026
Price chart
Active signals
EBS Signal Track Record
How signals performed across all stocks →What EBS's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 38 | -4.3% | 42% | October 5, 2026 |
| Bollinger Band Breakout | 25 | -8.0% | 40% | May 5, 2026 |
| Bollinger Band Breakdown | 20 | -2.9% | 40% | August 6, 2026 |
| Any 20-session window (baseline) | -3.0% | 45% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About EBS
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intravenous (ANTHRASIL), a…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 900
- Website
- emergentbiosolutions.com/
Fundamentals
- 1-day range
- $6.84$7.23
- Market cap
- $273.98M
- P/E (trailing)
- —
- P/E (forward)
- 6.86
- EPS (trailing)
- $-3.51
- Dividend yield
- —
- Beta
- 2.42
- Avg. volume
- 1.16M
How Emergent BioSolutions Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 27, 2026 · via SEC EDGAR / Finnhub
Forecasts
2 analyst ratings
Emergent BioSolutions Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- EBSEmergent BioSolutions Inc. Common Stock$6.38▼ 11.14%Market cap $273.98MP/E —$4.36$14.06
- ADAGAdagene Inc. American Depositary Shares$2.06▼ 14.17%Market cap $273.45MP/E —$1.3$4.85
- CLLSCellectis S.A. American Depositary Shares$1.04▼ 5.88%Market cap $270.42MP/E —$1.04$4.75
- BCYCBicycle Therapeutics plc American Depositary Shares$3.46▼ 3.89%Market cap $277.87MP/E —$3.33$9.08
- PRQRProQR Therapeutics N.V. Ordinary Shares$1.31▼ 9.66%Market cap $268.13MP/E —$1.33$3.1
- ELDNEledon Pharmaceuticals Inc. Common Stock$2.13▼ 6.17%Market cap $267.07MP/E —$1.35$4.6
- TRDAEntrada Therapeutics Inc. Common Stock$4.37▼ 8.58%Market cap $266.70MP/E —$4.11$16.45
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| EBS Emergent BioSolutions Inc. Common Stock | $273.98M | — | $6.38 | ▼ 11.14% | $4.36$14.06 |
| ADAG Adagene Inc. American Depositary Shares | $273.45M | — | $2.06 | ▼ 14.17% | $1.3$4.85 |
| CLLS Cellectis S.A. American Depositary Shares | $270.42M | — | $1.04 | ▼ 5.88% | $1.04$4.75 |
| BCYC Bicycle Therapeutics plc American Depositary Shares | $277.87M | — | $3.46 | ▼ 3.89% | $3.33$9.08 |
| PRQR ProQR Therapeutics N.V. Ordinary Shares | $268.13M | — | $1.31 | ▼ 9.66% | $1.33$3.1 |
| ELDN Eledon Pharmaceuticals Inc. Common Stock | $267.07M | — | $2.13 | ▼ 6.17% | $1.35$4.6 |
| TRDA Entrada Therapeutics Inc. Common Stock | $266.70M | — | $4.37 | ▼ 8.58% | $4.11$16.45 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- 'Russia Denies Report of Second Case of Illness in Siberia' - Bloombergbenzinga · 10/8/2026
- 'Russia Denies Report of Second Case of Illness in Siberia' - BloombergBenzinga · 10/8/2026
- Emergent Biosolutions (EBS) Soars 14.4%: Is Further Upside Left in the Stock?Yahoo · 10/6/2026
- NVAX, EBS, ARCT, MRNA Rally After Russia Plague Lab Worker's Death: Retail Traders Eye 'Contract Awards'Yahoo · 10/6/2026
- Novavax Shorts on Edge as Russia Plague Fears SpreadBenzinga · 10/5/2026
- Media Advisory: Emergent to Host Ribbon Cutting Ceremony at Canton Manufacturing FacilityYahoo · 9/15/2026
- Emergent: The MCM Engine Runs, But Naloxone Is Breaking DownSeekingAlpha · 9/15/2026
Insider Activity
Insider Actions →- Donald W. DeGolyer · October 7, 2026 · Sale17.8K @ $7.09
- Paul Anthony Williams · October 1, 2026 · Sale3.0K @ $6.53
- Paul Anthony Williams · July 1, 2026 · Sale3.0K @ $8.4
- William Hartzel · June 8, 2026 · Tax Withholding1.7K @ $8
- Paul Anthony Williams · June 8, 2026 · Tax Withholding694 @ $8
- Coleen Glessner · June 8, 2026 · Tax Withholding2.0K @ $8
- Richard S. Lindahl · June 8, 2026 · Tax Withholding4.0K @ $8
- Kathryn C. Zoon · May 1, 2026 · Sale1.1K @ $8.97
- Kathryn C. Zoon · May 1, 2026 · Sale16.1K @ $8.36
- Donald W. DeGolyer · May 1, 2026 · Sale954 @ $8.96
- Donald W. DeGolyer · May 1, 2026 · Sale14.5K @ $8.36
- Sujata Tyagi Dayal · May 1, 2026 · Sale980 @ $8.94
- Sujata Tyagi Dayal · May 1, 2026 · Sale12.8K @ $8.36
- Sujata Tyagi Dayal · April 30, 2026 · Grant11.3K
- Kathryn C. Zoon · April 30, 2026 · Grant11.3K
Institutional Ownership
March 31, 2026
- Total shares held
- 41.40M
- Total value held
- $321.76M
- Institutional holders
- 185
- Unknown4.34M
- Unknown2.85M
- Unknown2.76M
- Unknown2.43M
- Unknown2.26M
- Unknown1.51M
- Unknown1.38M
- Unknown1.27M
- Unknown1.20M
- Unknown1.11M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
EBS Shares Rise 14.4% After Russia Plague Lab Worker Death
EBS stock jumped 14.4% following the death of a Russian plague laboratory worker, a move that also lifted other vaccine makers such as Novavax, Arcturus and Moderna. The rally has drawn attention from retail traders who are looking for potential contract awards. The shares are currently trading near the $7.98 support level, which has been tested 20 times, and the RSI sits at 55.1, indicating neither overbought nor oversold conditions.
EBS Shares Rise 14.4% After Russia Plague Lab Worker Death. EBS stock jumped 14.4% following the death of a Russian plague laboratory worker, a move that also lifted other vaccine makers such as Novavax, Arcturus and Moderna. The rally has drawn attention from retail traders who are looking for potential contract awards. The shares are currently trading near the $7.98 support level, which has been tested 20 times, and the RSI sits at 55.1, indicating neither overbought nor oversold conditions.